Related Experiment Videos
A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice
K A Olson1, T C French, B L Vallee
1Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Abstract:
Human angiogenin, a potent inducer of neovascularization, is secreted by HT-29 colon adenocarcinoma cells. microgram doses of a monoclonal antibody that neutralizes the in vitro and in vivo activities of angiogenin prevent or delay the appearance of s.c. HT-29 tumors in athymic mice in a statistically significant, dose-dependent manner. The antibody is not cytotoxic to tumor cells in vitro, which indicates that inhibition of tumor growth most likely occurs by neutralization of the activity of angiogenin in vivo and further implies a critical role for angiogenin in the early development of HT-29 tumors. The results suggest a therapeutically useful approach to the treatment of angiogenin-dependent malignancy.
Insights
A monoclonal antibody targeting human angiogenin, a key factor in blood vessel formation, effectively inhibited the growth of HT-29 colon tumors in mice. This suggests angiogenin neutralization as a promising therapeutic strategy for certain cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Human angiogenin is a protein that promotes new blood vessel formation (neovascularization).
- HT-29 colon adenocarcinoma cells secrete angiogenin.
- Angiogenin plays a role in the early development of tumors.
Purpose of the Study:
- To investigate the therapeutic potential of neutralizing angiogenin in colon cancer.
- To determine if inhibiting angiogenin affects the growth of HT-29 tumors in vivo.
Main Methods:
- Administered microgram doses of a monoclonal antibody that neutralizes angiogenin.
- Observed the effect of the antibody on subcutaneous HT-29 tumor growth in athymic mice.
- Assessed antibody cytotoxicity to tumor cells in vitro.
Main Results:
- The anti-angiogenin antibody significantly prevented or delayed tumor appearance in a dose-dependent manner.
- The antibody did not exhibit direct cytotoxicity to HT-29 tumor cells in vitro.
- Tumor growth inhibition is attributed to in vivo angiogenin neutralization.
Conclusions:
- Angiogenin is critical for the early development of HT-29 colon tumors.
- Neutralizing angiogenin is a potentially effective therapeutic strategy for angiogenin-dependent malignancies.
- This approach offers a novel treatment avenue for colon cancer.